News

GSK and Miltenyi Biotec have formed a strategic collaboration seeking to optimise the manufacture and delivery of personalised gene therapies.

Scotland has unveiled a new £100-million strategy to tackle cancer by improving prevention, detection, diagnosis, treatment and after care for those affected by the disease.

In a rather unusual move, Eli Lilly has changed the endpoint of an ongoing Phase III trial assessing its experimental beta amyloid antibody solanezumab in patients with Alzheimer’s disease.

Sanofi and DiCE Molecules have formed a five-year global collaboration that aims to discover potential new therapeutics for up to 12 different targets within the French drug giant’s areas of strategic interest, including oncology, cardiovascular and diabetes.

Blueprint Medicines is collaborating with Roche on the discovery, development and commercialisation of up to five targeted cancer immunotherapies, in a deal potentially worth more than $1 billion.

The new All-Party Parliamentary Group on Personalised Medicine has had its official launch in the House of Commons this week, having been established to help the National Health Service and patients make best use of the increasing availability of cutting-edge technologies to provide more personalised health and care.

Community pharmacies are at risk of going out of business because of planned cuts to funding, which could potentially pull the plug on a vital lifeline for many elderly and vulnerable patients, the Local Government Association (LGA) is warning. 

The government has failed to act quickly enough to keep acute hospital trust finances afloat and put in place a “convincing plan” to close the huge “black hole” in NHS finances, says a damning new report by the Public Accounts Committee.

Roche’s ‘breakthrough’ immunotherapy atezolizumab is being given a priority review in the US on the back of Phase II data supporting its potential as a treatment for bladder cancer.

Shares in GW Pharmaceuticals surged nearly 140% as it emerged that experimental cannabinoid Epidiolex hit targets in the first major paediatric trial investigating its potential in a rare and very difficult to treat form of childhood epilepsy called Dravet syndrome.

Health officials are calling on the British public to check they are up-to-date with MMR vaccinations after a sharp rise in measles cases in London and the South-East.

US patients with ROS-1 positive non-small cell lung cancer (NSCLC) will no doubt welcome news that regulators have approved the first treatment for the condition, after expanding the scope of Pfizer’s Xalkori.

European regulators are undertaking a safety review of Gilead’s cancer drug Zydelig following a spike in serious adverse events observed in clinical trials.

GlaxoSmithKline has pulled out of a five-year deal with US biotech Five Prime for the development of its experimental cancer therapy FP-1039.  

European regulators have issued a green light for Teva’s planned $40.5-billion purchase of Allergan’s global generics business.